Pennington, NJ, United States of America

Nicholas Ronald Wurtz

This inventor holds 24 USPTO granted patents and 5 published patent applications and 13 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bristol-Myers Squibb Compnay, Exelixis Patent Company LLC. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicholas Ronald Wurtz. Retrieved from https://idiyas.com/inventor/nicholas-ronald-wurtz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 5)

% Patents Active = 91.7

EPO Patents = 13 (Patent Applications = 20)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 28(Granted Patents)

Company Filing History:

24 out of 3,742

Bristol-Myers Squibb Compnay

patents

2 out of 13

Exelixis Patent Company LLC

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

FPR2 Agonists

Myeloperoxidase Inhibitors

LXR Modulators

Piperidinone Compounds

Phenylpyrrolidinone

Triazolopyridine

Anticoagulants

Cyclopropyl Urea

Aryl Heterocycles

Oxopyrrolidine

Pyrazolone

Bicyclic Lactams

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758559 - RXFP1 agonists (2026-10-13),

2. 12679823 - Oxopyrrolidine FPR2 agonists (2026-07-14),

3. 12577206 - Pyrazolone formyl peptide 2 receptor agonists (2026-03-17),

4. 12565483 - Oxopyrrolidine urea FPR2 agonists (2026-03-03),

5. 12281108 - Pyrrolidinone derivatives as formyl peptide 2 receptor agonists (2025-04-21),

6. 11708327 - Phenylpyrrolidinone formyl peptide 2 receptor agonists (2023-07-25),

7. 11530183 - Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists (2022-12-20),

8. 11186544 - Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists (2021-11-30),

9. 11180490 - Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists (2021-11-23),

10. 11124494 - Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists (2021-09-21),

11. 11117861 - Phenylpyrrolidinone formyl peptide 2 receptor agonists (2021-09-14),

12. 11008317 - Triazolopyridine inhibitors of myeloperoxidase and/or EPX (2021-05-18),

13. 11008301 - Piperidinone formyl peptide 2 receptor agonists (2021-05-18),

14. 10981879 - Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase (2021-04-20),

15. 10717708 - Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists (2020-07-21),

Title: The Innovative Journey of Nicholas Ronald Wurtz

Introduction

Nicholas Ronald Wurtz, a distinguished inventor based in Pennington, NJ, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 19 patents. His work primarily focuses on compounds that target formyl peptide receptors, showcasing his commitment to advancing medical treatments for several serious health conditions.

Latest Patents

Some of Wurtz's latest patents highlight innovative compounds such as the "Phenylpyrrolidinone formyl peptide 2 receptor agonists". This patent relates to compounds of Formulae (I)-(IX), which act as agonists for formyl peptide 2 (FPR2) and formyl peptide 1 (FPR1) receptors. The innovations detailed in this patent include compositions and methods intended for the treatment of various diseases such as atherosclerosis, heart failure, and chronic obstructive pulmonary disease (COPD).

Additionally, he has developed "Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists", which also consists of compounds targeting the same receptors. This patent further emphasizes the therapeutic potential in treating the same range of diseases, marking a valuable contribution to medical science.

Career Highlights

Throughout his career, Nicholas has worked with notable companies in the pharmaceutical industry, including Bristol Myers Squibb Company and Exelixis Patent Company LLC. His experience in these organizations has been instrumental in shaping his innovative pursuits and advancing pharmaceutical research.

Collaborations

Collaboration has been a vital element of Nicholas's journey as an inventor. He has worked alongside talented professionals, including Ellen K. Kick and Pravin Sudhakar Shirude. These partnerships have fostered a collaborative environment that has enhanced research outputs and facilitated the development of both patented innovations.

Conclusion

Nicholas Ronald Wurtz stands out as a prominent figure in the realm of pharmaceutical inventions. With his extensive portfolio of patents and collaborations with leading organizations and professionals, he continues to contribute to critical advancements in medical treatment, emphasizing the importance of innovation in addressing healthcare challenges.

Profile summary based on public USPTO records.